BPC-157 vs TB-500
BPC-157 and TB-500 are the two most-referenced tissue-repair research peptides, often mentioned together in tissue-repair and wound-healing research contexts. Both have adjacent cognitive-relevance research angles via their CNS-injury and neuroregeneration research applications, but the two compounds occupy distinct compound-architecture and research-programme positioning.
At a glance
| BPC-157 | TB-500 | |
|---|---|---|
| Structural class | 15-amino-acid research peptide (gastric-juice derived) | Thymosin β4 fragment (LKKTETQ heptapeptide) |
| Origin research programme | Sikiric group (Zagreb, Croatia) | RegeneRx Biopharmaceuticals development |
| Primary route | Subcutaneous, intramuscular, or oral (research) | Subcutaneous or intramuscular |
| Signature research application | Gut repair, wound healing, tendon/ligament healing, vascular effects | Wound healing, cardiac repair, dermatology, neuroregeneration |
| Clinical evidence base | Extensive preclinical (Sikiric programme); no human clinical trials | Preclinical primary; some human clinical-trial exposure in dermatology and wound-healing |
| Cognitive-relevance research angle | CNS injury and behavioural-endpoint effects reported | Adult neurogenesis and spinal cord injury regeneration research |
| Evidence tier | C | C |
| UK status | No emc entry found (checked 17 October 2026) | No emc entry found (checked 17 October 2026) |
Origin and research-programme positioning
Sikiric Zagreb programme versus RegeneRx development context
BPC-157's origin and research-programme context is the Sikiric research group at the University of Zagreb, which has characterised the compound continuously across multiple decades. This concentrated single-programme origin provides methodological consistency across the wide range of tissue-repair contexts characterised (gut, wound, tendon, ligament, bone, vascular, and CNS) but limits independent replication by non-Sikiric-affiliated research groups.
TB-500's origin and research-programme context is more diverse — the compound was developed partly within RegeneRx Biopharmaceuticals' clinical-development framework, with additional academic research groups contributing to the preclinical characterisation. The evidence base includes some human clinical-trial exposure in dermatology and wound-healing indications, though the clinical-development trajectory has been mixed.
For research-tool positioning the two compounds provide substantially overlapping tissue-repair coverage with some distinctive strengths. BPC-157's breadth across gut, tendon, and vascular contexts is distinctive; TB-500's clinical-development exposure and adult-neurogenesis research applications are distinctive. Research designs frequently reference both compounds together in tissue-repair and wound-healing research contexts.
Cognitive-relevance research angles
CNS injury and neuroregeneration research applications
BPC-157's cognitive-relevance research angle is via reported effects in CNS injury models and behavioural-endpoint measures in various stress-and-injury contexts. The mechanism-of-action framing operates through vascular-endothelial effects, growth-factor modulation, and neurotransmitter-system effects. The evidence base for the specific CNS applications is smaller than for the tissue-repair applications but continues to be extended by ongoing research work.
TB-500's cognitive-relevance research angle is via reported effects on adult neurogenesis and spinal cord injury regeneration research applications. The mechanism-of-action framing operates through actin-related cytoskeletal modulation, angiogenesis, and immune-cell recruitment to tissue-injury contexts. The spinal cord injury research context has been particularly well-characterised.
For cognitive-decline research applications specifically, neither compound has a substantial cognitive-endpoint clinical evidence base. Both are research-tool positioned rather than cognitive-endpoint direct-intervention positioned; the cognitive-relevance is indirect via the tissue-repair and neuroregeneration mechanisms.